Immutep
Sydney
About Immutep
Immutep is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission, and soon starting a pilot trial for resected pancreatic cancer. Immutep is listed on the Australian stock exchange, on the NASDAQ in the US and in Germany on the Deutsche Börse in an entry standard.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $73.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2024)
- Ticker: asx:IMM
- Website: immutep.com
- Phone: +61 2 8315 7003
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immutep-48547 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.